AR109706A1 - INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g - Google Patents

INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g

Info

Publication number
AR109706A1
AR109706A1 ARP170102631A ARP170102631A AR109706A1 AR 109706 A1 AR109706 A1 AR 109706A1 AR P170102631 A ARP170102631 A AR P170102631A AR P170102631 A ARP170102631 A AR P170102631A AR 109706 A1 AR109706 A1 AR 109706A1
Authority
AR
Argentina
Prior art keywords
alkyl
phosfatidilinositol
quinasa
dual inhibitors
formula
Prior art date
Application number
ARP170102631A
Other languages
English (en)
Spanish (es)
Inventor
Ulf Brjesson
Peter Bold
Antonios Nikitidis
Christian Tyrchan
Konstantinos Karabelas
Matthew Perry
Jens Petersen
Mickael Mogemark
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR109706A1 publication Critical patent/AR109706A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ARP170102631A 2016-09-22 2017-09-22 INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g AR109706A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201662398006P 2016-09-22 2016-09-22

Publications (1)

Publication Number Publication Date
AR109706A1 true AR109706A1 (es) 2019-01-16

Family

ID=59966739

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP170102631A AR109706A1 (es) 2016-09-22 2017-09-22 INHIBIDORES DUALES DE FOSFATIDILINOSITOL 3 QUINASA d / g

Country Status (36)

Country Link
US (2) US10961236B2 (enExample)
EP (1) EP3515910B1 (enExample)
JP (1) JP6765516B2 (enExample)
KR (1) KR102226098B1 (enExample)
CN (1) CN109715623A (enExample)
AR (1) AR109706A1 (enExample)
AU (1) AU2017331940B2 (enExample)
BR (1) BR112019004719A2 (enExample)
CA (1) CA3036304A1 (enExample)
CL (1) CL2019000707A1 (enExample)
CO (1) CO2019003440A2 (enExample)
CR (1) CR20190200A (enExample)
CY (1) CY1123346T1 (enExample)
DK (1) DK3515910T3 (enExample)
DO (1) DOP2019000073A (enExample)
EA (1) EA036176B1 (enExample)
EC (1) ECSP19027780A (enExample)
ES (1) ES2818583T3 (enExample)
HR (1) HRP20201175T1 (enExample)
HU (1) HUE051634T2 (enExample)
IL (1) IL265298B (enExample)
JO (1) JOP20190052A1 (enExample)
LT (1) LT3515910T (enExample)
MA (1) MA46268B1 (enExample)
MX (2) MX381898B (enExample)
PE (1) PE20190909A1 (enExample)
PH (1) PH12019500615A1 (enExample)
PL (1) PL3515910T3 (enExample)
PT (1) PT3515910T (enExample)
RS (1) RS60764B1 (enExample)
SI (1) SI3515910T1 (enExample)
SM (1) SMT202000481T1 (enExample)
SV (1) SV2019005857A (enExample)
TW (1) TW201813967A (enExample)
UA (1) UA123558C2 (enExample)
WO (1) WO2018055040A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11161838B2 (en) 2018-11-13 2021-11-02 Incyte Corporation Heterocyclic derivatives as PI3K inhibitors
WO2020102216A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Substituted heterocyclic derivatives as pi3k inhibitors
WO2020102198A1 (en) 2018-11-13 2020-05-22 Incyte Corporation Heterocyclic derivatives as pi3k inhibitors
WO2020210379A1 (en) * 2019-04-10 2020-10-15 Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. Phosphatidylinositol 3-kinase inhibitors
AU2020288610A1 (en) 2019-06-04 2022-01-27 Arcus Biosciences, Inc. 2,3,5-trisubstituted pyrazolo[1,5-a]pyrimidine compounds
WO2022017371A1 (zh) * 2020-07-21 2022-01-27 中国医药研究开发中心有限公司 具有磷脂酰肌醇3-激酶δ和γ的双重抑制剂活性的杂环化合物及其医药用途
WO2022023456A1 (en) 2020-07-29 2022-02-03 Astrazeneca Ab Pharmaceutical compositions comprising nano embedded microparticles and methods of use
CN116813608B (zh) * 2023-06-08 2024-03-22 英矽智能科技(上海)有限公司 噻唑类化合物及其应用

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2257461T3 (es) * 2000-12-21 2006-08-01 Bristol-Myers Squibb Company Inhibidores de tiazolilo de tirosina quinasas de la familia tec.
GB0305152D0 (en) * 2003-03-06 2003-04-09 Novartis Ag Organic compounds
GB0320197D0 (en) * 2003-08-28 2003-10-01 Novartis Ag Organic compounds
JP2008543754A (ja) * 2005-06-09 2008-12-04 メルク エンド カムパニー インコーポレーテッド チェックポイントキナーゼの阻害剤
US7928140B2 (en) * 2007-08-02 2011-04-19 Amgen Inc. Benzothiazole PI3 kinase modulators for cancer treatment
UY33337A (es) 2010-10-18 2011-10-31 Respivert Ltd DERIVADOS SUSTITUIDOS DE 1H-PIRAZOL[ 3,4-d]PIRIMIDINA COMO INHIBIDORES DE LAS FOSFOINOSITIDA 3-QUINASAS
EP2734520B1 (en) 2011-07-19 2016-09-14 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
US9056877B2 (en) 2011-07-19 2015-06-16 Infinity Pharmaceuticals, Inc. Heterocyclic compounds and uses thereof
PE20141371A1 (es) 2011-08-29 2014-10-13 Infinity Pharmaceuticals Inc Compuestos heterociclicos y usos de los mismos
EP2763994A4 (en) 2011-10-04 2015-08-26 Gilead Calistoga Llc NEW QUINOXALINE INHIBITORS OF THE PI3K PATH
UA119315C2 (uk) 2012-07-03 2019-06-10 Гіліад Фармассет Елелсі Інгібітори вірусу гепатиту с
TW201446767A (zh) 2013-02-15 2014-12-16 Almirall Sa 作為磷脂肌醇3-激酶抑製劑之吡咯並三嗪衍生物
ES2672018T3 (es) 2013-07-02 2018-06-12 Rhizen Pharmaceuticals S.A. Inhibidores de proteína cinasa PI3K, particularmente inhibidores delta y/o gamma
UY35675A (es) 2013-07-24 2015-02-27 Novartis Ag Derivados sustituidos de quinazolin-4-ona
CN106661029B (zh) 2014-06-27 2019-04-05 理森制药股份公司 作为PI3δ和γ蛋白激酶的选择性双重抑制剂的取代色烯衍生物

Also Published As

Publication number Publication date
PT3515910T (pt) 2020-09-16
MA46268B1 (fr) 2020-08-31
AU2017331940B2 (en) 2020-03-12
CN109715623A (zh) 2019-05-03
UA123558C2 (uk) 2021-04-21
KR102226098B1 (ko) 2021-03-09
CR20190200A (es) 2019-06-07
KR20190049867A (ko) 2019-05-09
US20200308164A1 (en) 2020-10-01
US10961236B2 (en) 2021-03-30
PH12019500615A1 (en) 2019-06-03
MX381898B (es) 2025-03-13
ES2818583T3 (es) 2021-04-13
MX2019003194A (es) 2019-06-17
TW201813967A (zh) 2018-04-16
AU2017331940A1 (en) 2019-05-02
CA3036304A1 (en) 2018-03-29
EP3515910B1 (en) 2020-07-15
CL2019000707A1 (es) 2019-05-31
CY1123346T1 (el) 2022-03-24
SI3515910T1 (sl) 2020-09-30
JP2019529445A (ja) 2019-10-17
HUE051634T2 (hu) 2021-03-01
SV2019005857A (es) 2019-05-06
BR112019004719A2 (pt) 2019-05-28
RS60764B1 (sr) 2020-10-30
US20210246130A1 (en) 2021-08-12
SMT202000481T1 (it) 2020-11-10
EA201990664A1 (ru) 2019-08-30
EA036176B1 (ru) 2020-10-09
EP3515910A1 (en) 2019-07-31
DOP2019000073A (es) 2019-04-15
MX2021004748A (es) 2021-06-08
LT3515910T (lt) 2020-10-12
PL3515910T3 (pl) 2021-02-22
MA46268A (fr) 2019-07-31
ECSP19027780A (es) 2019-04-30
JOP20190052A1 (ar) 2019-03-21
HRP20201175T1 (hr) 2020-11-13
DK3515910T3 (da) 2020-08-31
IL265298A (en) 2019-05-30
CO2019003440A2 (es) 2019-04-12
IL265298B (en) 2020-09-30
WO2018055040A1 (en) 2018-03-29
PE20190909A1 (es) 2019-06-26
JP6765516B2 (ja) 2020-10-07

Similar Documents

Publication Publication Date Title
AR110400A1 (es) Compuestos de amino-triazolopiridina y su uso en el tratamiento del cáncer
AR119761A2 (es) Benzamidas sustituidas con 1,3-tiazol-2-ilo
AR101367A1 (es) Pirimidinonas como inhibidores del factor xia
NI201700020A (es) Compuestos de aminopirimidinilo como inhibidores de jak
AR109349A1 (es) Compuestos y usos
CL2020001218A1 (es) Compuestos útiles para inhibir a cdk7.
AR099177A1 (es) Determinadas (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
AR108710A1 (es) Compuestos modulares de fxr (nr1h4)
UY36121A (es) ?pirazolopiridinas y pirazolopirimidinas?.
AR105238A1 (es) Compuestos de benzoxacepina oxazolidinona y métodos de uso
AR101815A1 (es) Compuestos y composiciones como inhibidores de quinasa
AR089671A1 (es) 1,4-dihidropirimidinas 4,4-disustituidas y su uso como medicamentos para el tratamiento de la hepatitis b
AR099955A1 (es) Compuestos de heteroarilo o arilo bicíclicos fusionados
AR095426A1 (es) Inhibidores tripeptídicos de la epoxicetona proteasa
AR111494A1 (es) Compuestos de anilinoquinazolina c₅ y su uso en el tratamiento del cáncer
AR097082A1 (es) Compuestos terapéuticamente activos y sus métodos de uso
AR106053A1 (es) Compuestos imidazo[4,5-c]quinolin-2-ona y su uso para el tratamiento del cáncer
AR099228A1 (es) Inhibidores macrocíclicos de fxia que tienen grupos heterocíclicos
AR094553A1 (es) Formas de oxadiazolpirazina
AR112086A1 (es) Compuestos heteroaromáticos como inhibidores de vanina
MX387483B (es) Preparación farmacéutica.
AR109711A1 (es) Inhibidores de fosfatidilinositol 3-quinasa
AR095097A1 (es) Compuestos de fenoxietoxi
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
PH12017501523A1 (en) Selective bace1 inhibitors

Legal Events

Date Code Title Description
FB Suspension of granting procedure